Treasure Island Pharmaceuticals Class 1 anti-cancer drug HZB1006 capsule registration application accepted by the State Drug Administration

recently, Heilongjiang Treasure Island Pharmaceuticals announced that its sub-
company(Harbin TreasurePharmaceutical(research and development of 1 class of anti-cancernew drug(capsule registration application to obtain the NationalDrug(Supervisory Administration, the acceptance number CXHL1800138, CXHL1800138According to the company's announcement, HZB1006 capsules are by Harbin Treasure Pharmaceuticals and Shanghai Pharmaceutical Mingkang de Cond New Drug Development Co., Ltdin accordance with the signing of the "pan-FGFR inhibitors for the treatment of liver cancer 1 class of new drug project technology development contract", jointly research and development of a class of innovativedrugs(owned by Ha Treasure independent intellectual property rightson HZB1006 capsulesHZB1006 capsules are fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR)-based multi-kinase inhibitors, both cell inhibition and anti-angiogenic production of the dual role, in the preclinical liver cancer model evaluation, showing that the efficacy of the invivar is superior to similar market-listed control drugs, with better safety, efficacy and clinical development valueso far, the company in theproduct (research and development investment accumulated about 26 million yuan, the follow-up will further increase research and development investment." it is reported that the current with HZB1006 capsules with the same target of the listed drugs are German Bayer-made toluene solafithan tablets (the commodity name Dojime), Dojime in late 2005 by the United States FDA (approved for sale, is the first FDA approved for the treatment of advanced nephrocytic cell carcinoma targeted drugs."